GS
INO icon

GTS Securities’s Inovio Pharmaceuticals INO Stock Holding History

GTS Securities’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,017
Closed -$6.22K – 4143
2023
Q4 		$6.22K Sell
1,017
-58
-5% -$286 ﹤0.01% 3936
2023
Q3 		$5.02K Buy
+1,075
New +$5.94K ﹤0.01% 3833

Other funds holding INO

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

GTS Securities's INO Position: Q2 2024 in Review

GTS Securities sold out of Inovio Pharmaceuticals (INO) in Q2 2024, closing a stake of 23,479 shares — an estimated $326K sold.

GTS Securities first reported a position in INO in Q3 2023 and held it in 3 quarters. The position peaked at $326K in Q1 2024. 96 funds tracked by Wall St. Rank hold INO as of Q2 2024.

  • GTS Securities reported no remaining Inovio Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • GTS Securities sold 23,479 Inovio Pharmaceuticals shares in Q2 2024, an estimated $326K.
  • GTS Securities first reported a position in Inovio Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • GTS Securities's Inovio Pharmaceuticals position peaked at $326K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2024.

Based on GTS Securities's 13F filing for Q2 2024, filed 14 Aug 2024.